Based on the Unicycive Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Unicycive Therapeutics Inc is USD 4.33 over the next 12 months. Unicycive Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Unicycive Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Unicycive Therapeutics Inc’s stock price was USD 0.64. Unicycive Therapeutics Inc’s stock price has changed by -17.06% over the past week, +12.82% over the past month and -3.39% over the last year.
No recent analyst target price found for Unicycive Therapeutics Inc
No recent average analyst rating found for Unicycive Therapeutics Inc
Company Overview Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California. Read Less
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for a...Read More
Frequently Asked Questions About Unicycive Therapeutics Inc (UNCY) Stock
Based on ratings from 3 analysts Unicycive Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on UNCY's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for UNCY is USD 4.33 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on UNCY's stock to indicate if its overvalued.
The last closing price of UNCY's stock was USD 0.64.
The most recent market capitalization for UNCY is USD 0.07B.
Based on targets from 3 analysts, the average taret price for UNCY is projected at USD 4.33 over the next 12 months.
This means that UNCY's stock price may go up by +579.21% over the next 12 months.
We can't find any ETFs which contains Unicycive Therapeutics Inc's stock.
As per our most recent records Unicycive Therapeutics Inc has 22 Employees.
Unicycive Therapeutics Inc's registered address is 4300 El Camino Real, Los Altos, CA, United States, 94022.
You can get more information about it from Unicycive Therapeutics Inc's website at https://unicycive.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Unicycive Therapeutics Inc (UNCY) Stock
Based on ratings from 3 analysts Unicycive Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on UNCY's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for UNCY is USD 4.33 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on UNCY's stock to indicate if its overvalued.
The last closing price of UNCY's stock was USD 0.64.
The most recent market capitalization for UNCY is USD 0.07B.
Based on targets from 3 analysts, the average taret price for UNCY is projected at USD 4.33 over the next 12 months.
This means that UNCY's stock price may go up by +579.21% over the next 12 months.
We can't find any ETFs which contains Unicycive Therapeutics Inc's stock.
As per our most recent records Unicycive Therapeutics Inc has 22 Employees.
Unicycive Therapeutics Inc's registered address is 4300 El Camino Real, Los Altos, CA, United States, 94022.
You can get more information about it from Unicycive Therapeutics Inc's website at https://unicycive.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for UNCY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
